Category Archives: Adult Stem Cells


Storing Stem Cells In Teeth For Your Familys Future Health

Protect your family's future health.

Secure their stem cells today.

Bank the valuable stem cells found in

baby teeth and wisdom teeth.

Researchers at the National Institutes of Health (NIH) discovered a rich source of adult stem cells in teeth the stem cells that naturally repair your body. Scientists aredirecting stem cells so they grow into almost any type of human cell, including heart, brain, nerve, cartilage, bone, liver and insulin producing pancreatic beta cells.

AAOMS - American Association of Oral and Maxillofacial Surgeons

Video is not visible, most likely your browser does not support HTML5 video

Doctors recommend StemSave stem cell banking for the cryopreservation of powerful adult stem cells from deciduous teeth (baby teeth), wisdom teeth or permanent teethwith healthy dentalpulp.

Easy OnlineEnrollment

StemSave Stem Cell Banking exclusively recovers and stores non-embryonic stem cells. Dental Stem Cells are also known asDSC, DASC, DPSC, or SHED cellsand are classified as atype of adult stem cells.

Continue reading here:
Storing Stem Cells In Teeth For Your Familys Future Health

Stem Cells Market – Global Industry Analysis, Size, Share …

Table of Content

Chapter 1 Preface

1.1 Report Description

1.2 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Market Overview

3.1 Market Trends and Future Outlook

3.1.1 Global Stem Cells Market, 2010 2018 (USD Billion)

3.2 Market Dynamics

3.2.1 Market Drivers

3.2.1.1 Unmet Medical Needs

3.2.1.2 Increasing Government Support

3.2.1.3 Growing Medical Tourism

3.2.1.4 Rising Stem Cells Banking Services

3.2.1.5 Impact Analysis of the Market Drivers

3.2.2 Market Restraints

3.2.2.1 High Cost of Treatment

3.2.2.2 Government Regulations against Unethical Harvesting of Stem Cells

3.2.2.3 Impact Analysis of the Market Restraints

3.2.3 Market Opportunities

3.2.3.1 Rising Neurodegenerative Disease Patients

3.2.3.2 Increasing Disposable Income in Emerging Nations

3.2.3.3 Replacing Animal Tissue in Drug Discovery

3.2.3.4 Growing Contract Research Industry

3.2.4 Porters Five Forces Analysis for the Global Stem Cells Market

3.2.4.1 Bargaining Power of Suppliers

3.2.4.2 Bargaining Power of Buyers

3.2.4.3 Threat of New Entrants

3.2.4.4 Threat of Substitutes

3.2.5 Competitive Rivalry

3.3 Market Attractiveness

3.3.1 Market Attractiveness Analysis of the Global Stem Cells Market, By Geography

Chapter 4 Global Stem Cells Market, By Products

4.1 Market Segmentation: Global Stem Cells Market, By Products

4.2 Overview

4.3 Adult Stem Cells Market, 2010 2018 (USD Billion)

4.3.1 Hematopoietic Stem Cells Market, 2010 2018 (USD Billion)

4.3.2 Mesenchymal Stem Cells Market, 2010 2018 (USD Billion)

4.3.3 Neuronal Stem Cells Market, 2010 2018 (USD Billion)

4.3.4 Dental Stem Cells (Mesenchymal Stem Cells, Neuronal Stem Cells) Market, 2010 2018 (USD Billion)

4.3.5 Umbilical Cord Stem Cells (Hematopoietic Stem Cells, Mesenchymal Stem Cells) Market, 2010 2018 (USD Billion)

4.4 Human Embryonic Stem Cells Market, 2010 2018 (USD Billion)

4.5 Induced Pluripotent Stem Cells Market, 2010 2018 (USD Billion)

4.6 Rat Neural Stem Cells Market, 2010 2018 (USD Billion)

4.7 Very Small Embryonic-Like Stem Cells Market, 2010 2018 (USD Billion)

Chapter 5 Global Stem Cells Market, By Technology

5.1 Market Segmentation: Global Stem Cells Market, By Technology

5.2 Overview

5.3 Global Stem Cell Acquisition Market, 2010 2018 (USD Billion)

5.3.1 Global Bone Marrow Harvest for Stem Cells, 2010 2018 (USD Billion)

5.3.2 Global Apheresis for Stem Cells Market, 2010 2018 (USD Billion)

5.3.3 Global Umbilical Cord Blood Market, 2010 2018 (USD Billion)

5.4 Global Stem Cell Production Market, 2010 2018 (USD Billion)

5.4.1 Global Therapeutic Cloning for Stem Cells Market, 2010 2018 (USD Billion)

5.4.2 Global Stem Cells Production By In Vitro Fertilization Market, 2010 2018 (USD Billion)

5.4.3 Global Stem Cell Isolation Market, 2010 2018 (USD Billion)

5.4.4 Global Stem Cell Culture Market, 2010 2018 (USD Billion)

5.5 Global Stem Cell Cryopreservation Market, 2010 2018 (USD Billion)

5.6 Global Stem Cells Expansion and Sub-Culture Market, 2010 2018 (USD Billion)

Chapter 6 Global Stem Cells Market, By Application

6.1 Market Segmentation: Global Stem Cells Market, By Application

6.2 Overview

6.3 Global Stem Cells Market in Regenerative Medicine, 2010 2018 (USD Billion)

6.3.1 Stem Cells Market in Neurology, 2010 2018 (USD Billion)

6.3.2 Global Stem Cells Market in Orthopedics, 2010 2018 (USD Billion)

6.3.3 Global Stem Cells Market in Oncology, 2010 2018 (USD Billion)

6.3.4 Global Stem Cells Market in Hematology, 2010 2018 (USD Billion)

6.3.5 Global Stem Cells Market for Cardiovascular and Myocardial Infarction, 2010 2018 (USD Billion)

6.3.6 Global Stem Cells Market for Injuries, 2010 2018 (USD Billion)

6.3.6.1 Global Stem Cells Market for Wound Care, 2010 2018 (USD Billion)

6.3.6.2 Global Stem Cells Market for Spinal Cord Injuries, 2010 2018 (USD Billion)

6.3.6.3 Global Stem Cells Market for Other (Joint Injuries, Eye Injuries, Lacerations and Concussions) Injuries, 2010 2018 (USD Billion)

6.3.7 Global Stem Cells Market for Diabetes, 2010 2018 (USD Billion)

6.3.8 Global Stem Cells Market for Liver Disorders, 2010 2018 (USD Billion)

6.3.9 Global Stem Cells Market for Incontinence, 2010 2018 (USD Billion)

6.3.10 Global Stem Cells Market for Other (Crohns Disease, Infertility, Immunodeficiency Disorder, Organ Transplants, Ophthalmic Disorder) Regenerative Medicine Applications, 2010 2018 (USD Billion)

6.4 Global Stem Cells Market in Drug Discovery and Development, 2010 2018 (USD Billion)

Chapter 7 Global Stem Cells Market, By Geography

7.1 Overview

7.2 North America

7.2.1 North America Stem Cells Market, 20102018 (USD Billion)

7.3 Europe

7.3.1 Europe Stem Cells Market, 20102018 (USD Billion)

7.4 Asia

7.4.1 Asia Stem Cells Market, 20102018 (USD Billion)

7.5 Rest of the World (Row)

7.5.1 Row Stem Cells Market, 20102018 (USD Billion)

Chapter 8 Competitive Landscape

8.1 Heat Map Analysis for the Key Market Players

8.1.1 Advanced Cell Technology Inc.

8.1.2 STEMCELL Technologies Inc.

8.1.3 Cellular Engineering Technologies Inc.

See the original post here:
Stem Cells Market - Global Industry Analysis, Size, Share ...

Adult Stem Cells and Regeneration | HHMI BioInteractive

Mature organisms have stem cells of various sorts, called adult stem cells. Adult stem cells supply cells that compensate for the loss of cells from normal cell death and turnover, such as the ever-dying cells of our skin, our blood, and the lining of our gut. They are also an essential source of cells for healing and regeneration in response to injury. Some animals, such as sea stars, newts, and flatworms, are capable of dramatic feats of regeneration, producing replacement limbs, eyes, or most of a body. It is an evolutionary puzzle why mammals have more limited powers of regeneration.

Researchers are interested in pinpointing where adult stem cells reside and in understanding how flexible adult stem cells are in their ability to produce divergent cells such as muscle and red blood cells. Understanding the sources and the rules for the differentiation of adult stem cells is essential for tapping their therapeutic potential. Since consenting adults can provide adult stem cells, some people think that adult stem cells may be a less controversial area of research than embryonic stem cells.

Continue reading here:
Adult Stem Cells and Regeneration | HHMI BioInteractive

Treatment for Chronic Obstructive Pulmonary Disease Dallas

Chronic Obstructive Lung Disease (COPD) is a debilitating lung condition that leaves patients unable to breathe or enjoy life. It is also known as emphysema, chronic bronchitis and chronic obstructive asthma. COPD is rated as the third leading killer in the United States, killing approximately 120,000 individuals a year. Persons suffering from COPD also experience chronic disability and often a low quality of life. Sufferers also require a large amount of medical care with its expense and the need to stay near medical facilities and personnel. COPD is a very limiting and deadly disease.

This paper is designed to help readers gain a greater understanding of the use of adult stem cells for COPD and offer a framework for evaluating if stem cell treatment is a potential step for you or your loved one. We will cover the following:

Feel free to skip to sections that provide information that is helpful to you.

For more information including definitions and descriptions of COPD visit: http://www.lung.org/lung-disease/copd/ http://www.mayoclinic.com/health/copd/DS00916

Skip to next section

COPD is a chronic condition and therefore typically requires long term medications. The commonly used treatment options are:

With the exception of surgery, these treatment options are all considered supportive. They help the symptoms but do not change the underlying disease. A simplified diagram of these treatments is:

A COPD patient may be prescribed one, several or all of these at one time or another during the course of their illness. Some patients suffer without using any treatments. The effectiveness of treatment varies greatly both between patients and over the course of the illness. Many patients with COPD do very well for many years with exercise with or without medications.

For more information on the treatment of COPD see: http://www.lung.org/lung-disease/copd/living-with-copd/copd-management-tools.html or http://www.guideline.gov/content.aspx?id=23801

If you are a person doing well using these options, this might not be the right time to consider adult stem cell treatment.

Skip to next section

If you are doing well with your current medical therapy, you may not be an ideal candidate for adult stem cell therapy. Persons should consider adult stem cell therapy for COPD include:

Lung changes in COPD

Adult stem cell therapy DOES NOT assure a response in these patients. However, it does offer an alternative that they may wish to consider. We will discuss results below.

Skip to next section

All stem cells, no matter their source, share two important characteristics:

When we obtain stem cells from mature adult tissues they are referred to as adult stem cells. As with all stem cells, the potential exists for adult stem cells to become any type of cell and then make new copies of the new cell type. This ability to become any type of cell and then make as many cells as needed is the reason for so much interest in adult stem cells. We refer to the process of obtaining adult stem cells as harvesting. To be a good tissue for harvesting, a tissue should be easy to harvest and have an abundant number of stem cells. The two tissues that most readily meet these requirements are bone marrow and fat.

Adult stem cells taken from fat are also known as adipose derived adult stem cells. Stem cells from fat have become increasingly attractive because stem cells from fat are easier to obtain and exist in larger numbers than bone marrow adult stem cells.

For more information on stem cells visit:

What are stem cellsor California Stem Cell Center

Skip to next section

It is a simple process to harvest adult stem cells from fat. First we select an area to take the fat like the stomach or leg. The area is marked and sterilized. Next a local anesthetic solution is injected into the area through a small incision. Suction is applied using a syringe with a special tool called a cannula attached. Typically 50 ml (about 1 1.2 oz.) of fat is suctioned for processing.

There can be some swelling and /or bruising after the harvesting procedure. Swelling and bruising typically resolve in about 2-3 weeks. Patients are given a prescription for pain medications in case they need them. An antibiotic is given before the procedure. Since the procedure is done sterilely, no further antibiotics are needed. Applying ice to the harvest area for a few days after the procedure reduces the swelling and bruising.

After harvesting we take the fat and do some simple processing to isolate the adult stem cells. When finished, the final product is called Stromal Vascular Fraction (SVF). SVF is a very powerful mixture of adult stem cells and growth factors. Growth factors are the chemical messengers our bodies use to promote healing and cell growth. Growth factors have sometimes been referred to as text messages between cells. A typical batch of SVF contains up to about 25 million adult stem cells. Each SVF batch also contains a large amount of growth factors. The growth factors harvested in SVF tend to be highly anti-inflammatory. After harvesting and processing the SVF is now ready to be deployed for your COPD. It can also be used for many other disorders. A number of deployment protocols under investigation for a large number of disorders.

For more about the harvesting process please visit: Harvesting adult stem cells

Skip to next section

We refer to the process of actually using the adult stem cells/SVF ( Stromal Vascular Fraction ) as deployment. The typical deployment for COPD is intravenous. We also nebulize a small amount of the stme cells/SVF and have the patient inhale it.

The IV is started in the office and the stem cells/SVF is injected into a small IV bag. This is then given to the patient over 20-30 minutes. The nebulizer is given during the time the IV is running. When the nebulizer and IV are finished, the IV is discontinued and the patient is discharged.

Skip to next section

Although research is in progress, there are currently no treatment groups large enough to answer this question conclusively. It is important to be aware that the Food and Drug Administration (FDA) has NOT approved the use of adult stem cells/SVF ( Stromal Vascular Fraction ) for any disorder including COPD. Understanding these issues, we do have enough experience to talk about early trends in therapy.

Around 90% of patients respond to deployment with adult stem cells/SVF. The most common response is an increase in exercise ability. Patients feel they can walk further without becoming winded. Patients also note an increase in their oxygen saturation levels (O2 sat). Most patients respond to only one deployment. Some require a repeat deployment in 3-6 months.

This is one of the most common questions asked by our adult stem cell/SVF ( Stromal Vascular Fraction ) patients. Response to deployment for COPD varies from a few days to about 3 months. If a patient has not seen a significant improvement after about 3 months, we recommend a repeat deployment. Many patients continue to see improvement for several months. When they plateau or regress, we then consider a repeat deployment for them as well.

Most of the time repeat deployment is done after the patient has seen some improvement and more improvement is sought. Occasionally, repeat deployment is done because the patient has lost some improvement previously seen. The question of how many deployments are best and how often they are needed is an area of intense interest and study at this time. It is too early to say conclusively that adult stem cells treatment promotes the growth of new lung cells.

We hope we have answered the majority of your questions. If you have others or wish to schedule a consultation please call: 214-420-7970.

Follow this link:
Treatment for Chronic Obstructive Pulmonary Disease Dallas

Stem Cell Basics V. | stemcells.nih.gov

Human embryonic and adult stem cells each have advantages and disadvantages regarding potential use for cell-based regenerative therapies. One major difference between adult and embryonic stem cells is their different abilities in the number and type of differentiated cell types they can become. Embryonic stem cells can become all cell types of the body because they are pluripotent. Adult stem cells are thought to be limited to differentiating into different cell types of their tissue of origin.

Embryonic stem cells can be grown relatively easily in culture. Adult stem cells are rare in mature tissues, so isolating these cells from an adult tissue is challenging, and methods to expand their numbers in cell culture have not yet been worked out. This is an important distinction, as large numbers of cells are needed for stem cell replacement therapies.

Scientists believe that tissues derived from embryonic and adult stem cells may differ in the likelihood of being rejected after transplantation. We don't yet know for certainwhether tissues derived from embryonic stem cells would cause transplant rejection, since relatively few clinical trialshave testedthe safety of transplanted cells derived from hESCS.

Adult stem cells, and tissues derived from them, are currently believed less likely to initiate rejection after transplantation. This is because a patient's own cells could be expanded in culture, coaxed into assuming a specific cell type (differentiation), and then reintroduced into the patient. The use of adult stem cells and tissues derived from the patient's own adult stem cells would mean that the cells are less likely to be rejected by the immune system. This represents a significant advantage, as immune rejection can be circumvented only by continuous administration of immunosuppressive drugs, and the drugs themselves may cause deleterious side effects.

Previous|V. What are the similarities and differences between embryonic and adult stem cells?|Next

Originally posted here:
Stem Cell Basics V. | stemcells.nih.gov

Adult Stem Cells: The Best Kept Secret In Medicine …

Stem cell therapies and their lifesaving results are arguably the best kept medical secret. Stem cells are currently being used in several thousand FDA-approved clinical trials, are treating tens of thousands of patients every year, and cumulatively over 1.5 million people have been treated to date. Yet these numbers, and the lifesaving results from stem cells for dozens of conditions, are unknown to most. Why the information blackout? Perhaps for lack of an adjective.

You see, those heartening numbers are all due to adult stem cells. Long ignored by the media and disparaged even by many in the scientific community, adult stem cells those not dependent on the destruction of embryos are the true gold standard for stem cells, especially when it comes to treating patients.

A recent New York Times piece provides a perfect example of the disinformation campaign. Early on, the author discusses the theoretical nature of stem cell treatments and bemoans the fact that progress is slow, almost all the research is still in mice or petri dishes, and The very few clinical trials that have begun are still in the earliest phase.

Whether through ignorance or bias, the sole focus is clearly on embryonic stem cells. Such writing, however, serves to confuse, not illuminate, the facts about stem cells and therapies.

Contrary to the blinkered portrayal of stem cells in the article, there are in fact almost 3,500 ongoing or completed clinical trials using adult stem cells, listed in the NIH/FDA-approved database. Moreover, large numbers of patients have been treated with adult stem cells. In 2012 there were almost 70,000 patients treated around the globe in that year alone, and almost 20,000 patients treated in just the U.S. in 2014. Cumulatively, its been documented that as of December 2012, there had already been over one million adult stem cell transplants. This means that now, over 1.5 million patients have had their lives saved and health improved by adult stem cell transplants.

Follow LifeNews.com on Instagram for pro-life pictures and the latest pro-life news.

Our focus is indeed on adult stem cells both because they are efficacious for patients, as well as because adult stem cells are derived without the destruction of the stem cell donor, unlike embryonic stem cells and fetal stem cells. Both positions are based on the facts of biology.

The New York Times Kolata criticizes various stem cell clinics within the U.S., primarily via a paper by two long-time proponents of embryonic stem cells (though this is not disclosed in the article or in the paper), but paints a broad-brush across clinics operating legally and ethically as well as the shady operators. It then juxtaposes the critique of U.S. stem cell clinics with the tragic story of a patient who traveled to three different overseas clinics to receive stem cell injections and developed a growing mass of cells on his spine from at least one of the injections.

The implied warning is that all U.S. adult stem cell clinics are using similar methods, and, by extension, their patients may experience similar problems. Indeed, many clinics are offshore to avoid FDA rules, but yet again the article drops adjectives and sows confusion. The New England Journal of Medicine source on the case notes that the patient supposedly received proliferating cells including embryonic and fetal stem cells.

Certainly all clinics should operate within appropriate ethical and legal boundaries and patients should receive all information, including published background and whether the cells being used are adult, fetal, or embryonic; this is simply a matter of getting full informed consent. But fearmongering and misinformation help neither the patients nor the science.

The stem cell science deniers continue to denigrate adult stem cells, denying their successes or even at times their existence by dropping the necessary, descriptive adjective. But for patients, adult stem cells are the true gold standard for stem cells. The hope of adult stem cells is being realized right now, for thousands of people around the globe. Those stories, those doctors, those patients who have been helped by adult stem cell treatments, deserve to be heard. People like Cindy Schroeder who thought she was given a death sentence when she was diagnosed with multiple myeloma.

But Cindys doctor was informed on the facts of modern medicine, and was able to inform Cindy and her family that there was hopefrom adult stem cells. Over a year after her stem cell treatment, Cindy leads a full, active life and her family is closer than ever. Her story, like that of thousands of others, is not theoretical; its real adult stem cell science.

Read more:
Adult Stem Cells: The Best Kept Secret In Medicine ...

Adult Stem Cells: The Best Kept Secret In Medicine | The …

5190395

Stem cell therapies and their lifesaving results are arguably the best kept medical secret. Stem cells are currently being used in several thousand FDA-approved clinical trials, are treating tens of thousands of patients every year, and cumulatively over 1.5 million people have been treated to date. Yet these numbers, and the lifesaving results from stem cells for dozens of conditions, are unknown to most. Why the information blackout? Perhaps for lack of an adjective.

You see, those heartening numbers are all due to adult stem cells. Long ignored by the media and disparaged even by many in the scientific community, adult stem cells those not dependent on the destruction of embryos are the true gold standard for stem cells, especially when it comes to treating patients.

A recent New York Times piece provides a perfect example of the disinformation campaign. Early on, the author discusses the theoretical nature of stem cell treatments and bemoans the fact that progress is slow, almost all the research is still in mice or petri dishes, and The very few clinical trials that have begun are still in the earliest phase.

Whether through ignorance or bias, the sole focus is clearly on embryonic stem cells. Such writing, however, serves to confuse, not illuminate, the facts about stem cells and therapies.

Contrary to the blinkered portrayal of stem cells in the article, there are in fact almost 3,500 ongoing or completed clinical trials using adult stem cells, listed in the NIH/FDA-approved database. Moreover, large numbers of patients have been treated with adult stem cells. In 2012 there were almost 70,000 patients treated around the globe in that year alone, and almost 20,000 patients treated in just the U.S. in 2014. Cumulatively, its been documented that as of December 2012, there had already been over one million adult stem cell transplants. This means that now, over 1.5 million patients have had their lives saved and health improved by adult stem cell transplants.

Our focus is indeed on adult stem cells both because they are efficacious for patients, as well as because adult stem cells are derived without the destruction of the stem cell donor, unlike embryonic stem cells and fetal stem cells. Both positions are based on the facts of biology.

The New York Times Kolata criticizes various stem cell clinics within the U.S., primarily via a paper by two long-time proponents of embryonic stem cells (though this is not disclosed in the article or in the paper), but paints a broad-brush across clinics operating legally and ethically as well as the shady operators. It then juxtaposes the critique of U.S. stem cell clinics with the tragic story of a patient who traveled to three different overseas clinics to receive stem cell injections and developed a growing mass of cells on his spine from at least one of the injections. The implied warning is that all U.S. adult stem cell clinics are using similar methods, and, by extension, their patients may experience similar problems. Indeed, many clinics are offshore to avoid FDA rules, but yet again the article drops adjectives and sows confusion. The New England Journal of Medicine source on the case notes that the patient supposedly received proliferating cells including embryonic and fetal stem cells. Certainly all clinics should operate within appropriate ethical and legal boundaries and patients should receive all information, including published background and whether the cells being used are adult, fetal, or embryonic; this is simply a matter of getting full informed consent. But fearmongering and misinformation help neither the patients nor the science.

The stem cell science deniers continue to denigrate adult stem cells, denying their successes or even at times their existence by dropping the necessary, descriptive adjective. But for patients, adult stem cells are the true gold standard for stem cells. The hope of adult stem cells is being realized right now, for thousands of people around the globe. Those stories, those doctors, those patients who have been helped by adult stem cell treatments, deserve to be heard. People like Cindy Schroeder who thought she was given a death sentence when she was diagnosed with multiple myeloma. But Cindys doctor was informed on the facts of modern medicine, and was able to inform Cindy and her family that there was hopefrom adult stem cells. Over a year after her stem cell treatment, Cindy leads a full, active life and her family is closer than ever. Her story, like that of thousands of others, is not theoretical; its real adult stem cell science.

Dr. David A. Prentice, VP & Research Director for the Charlotte Lozier Institute as well as Adjunct Professor of Molecular Genetics at the John Paul II Institute, The Catholic University of America, and an Advisory Board Member for the Midwest Stem Cell Therapy Center.

See the original post:
Adult Stem Cells: The Best Kept Secret In Medicine | The ...

Inducible Site-Specific Recombination in Neural Stem …

Genesis. Author manuscript; available in PMC 2009 Jul 10.

Published in final edited form as:

PMCID: PMC2708938

NIHMSID: NIHMS128325

Department of Developmental Biology and Kent Waldrep Foundation Center for Basic Neuroscience Research on Nerve Growth and Regeneration, University of Texas Southwestern Medical Center, Dallas, Texas

Jian Chen and Chang-Hyuk Kwon contributed equally to this work.

To establish a genetic tool for manipulating the neural stem/progenitor cell (NSC) lineage in a temporally controlled manner, we generated a transgenic mouse line carrying an NSC-specific nestin promoter/enhancer expressing a fusion protein encoding Cre recombinase coupled to modified estrogen receptor ligand-binding domain (ERT2). In the background of the Cre reporter mouse strain Rosa26lacZ, we show that the fusion CreERT2 recombinase is normally silent but can be activated by the estrogen analog tamoxifen both in utero, in infancy, and in adulthood. As assayed by -galactosidase activity in embryonic stages, tamoxifen activates Cre recombinase exclusively in neurogenic cells and their progeny. This property persists in adult mice, but Cre activity can also be detected in granule neurons and Bergmann glia at the anterior of the cerebellum, in piriform cortex, optic nerve, and some peripheral ganglia. No obvious Cre activity was observed outside of the nervous system. Thus, the nestin regulated inducible Cre mouse line provides a powerful tool for studying the physiology and lineage of NSCs.

Keywords: Cre-ERT2, nestin, neural stem cells, tamoxifen, transgenic mouse, recombination

The recognition that the adult brain retains stem cells (NSCs) has fundamentally changed our view of brain plasticity (Lie et al., 2004; Ming and Song, 2005; Zhao et al., 2008). It also raises the hope of cell replacement therapy for neurodegenerative disease (Lie et al., 2004). Adult neurogenesis in the subventricular zone (SVZ) of the lateral ventricles serves to replenish olfactory bulb (OB) interneurons via the rostral migratory stream (RMS). In the dentate gyrus, neurogenesis in the subgranular layer (SGL) generates synaptically active granule neurons and has been implicated in learning, memory and mood disorders in rodents (Li et al., 2008; Ming and Song, 2005; Zhang et al., 2008; Zhao et al., 2008). The development of conditional mutant alleles using the Cre/loxP system has permitted circumvention of early lethality observed when many genes are mutated by traditional knockout, thus offering the opportunity to study gene function with spatial control (Mak, 2007). A further refinement of this technology has been the development of inducible Cre transgenes that permit temporal control of gene recombination and inactivation (Feil et al., 1997; Hayashi and McMahon, 2002). Fusion of the Cre recombinase protein with a modified estrogen receptor ligand-binding domain (ERT2) causes sequestering of the fusion protein in the cytoplasm where it cannot mediate loxP recombination. Application of estrogen or estrogen analogs, however, causes translocation of the Cre-ERT2 fusion protein to the nucleus where recombination can then be achieved.

To achieve temporal ablation of genes in the neural stem cell lineage, we have constructed a tamoxifen-inducible Cre transgene that is regulated by the neurogenic lineage specific promoter/enhancer of the nestin gene. Nestin is an intermediate filament protein specifically expressed in neural stem/progenitor cells in both developing central nervous system and adult brain. The regulatory element driving neural-specific nestin expression has been mapped to the second intron of the nestin gene (Lendahl et al., 1990; Zimmerman et al., 1994). As detailed in our studies, we show that the transgene is silent in the absence of estrogen analog. Upon activation, the expression is robust and recombination is elicited primarily in the principal neurogenic niches. Additional expression is confined to the cerebellum, certain peripheral nerves, and to the piriform cortex, a potentially novel site of neurogenesis.

The Cre-ERT2 cDNA was placed under the control of a 5.6 kb rat nestin 5 regulatory element and followed by the 668 bp of inversed nestin second intron (). Six transgenic lines were obtained after pronuclear injection and four underwent germline transmission. To assay Cre recombinase activity after induction, we crossed the CreERT2 lines with Rosa26-stop-lacZ (Rosa26lacZ) reporter mice. The Rosa26lacZ mice require Cre-mediated recombination for -galactosidase gene activation due to a stop cassette flanked by loxP sites upstream of the lacZ gene. To assess inducibility of the Cre transgene, sunflower oil vehicle (150 l) or the estrogen analog tamoxifen (1 mg) was injected into pregnant mice at embryonic day 12.5 (E12.5) and the embryos were dissected out at E14.5 for whole mount X-gal staining. In a Rosa26lacZ reporter background, exposure of the four transgenic lines to tamoxifen revealed that only two of the lines (Line 8 and Line 73) exhibited recombination activity ( and not shown). Moreover, comparison of Cre activity upon induction was similar although Line 8 was leaky, having minor but detectable Cre activity in the absence of tamoxifen. In contrast, Line 73 (Nes73-CreERT2) showed no signs of Cre activity in the absence of tamoxifen and the blue X-gal staining was found predominantly in embryonic brain and spinal cord where most nestin-positive neural progenitors are located ().

Transgene construct and tamoxifen inducibility. (a) Structure of the Nestin-CreERT2 transgene consisting of the rat nestin promoter/enhancer, cDNA encoding the CreERT2 fusion protein and inversely oriented Nestin second intron. (b) Transgene induction ...

The temporal control of Cre activity allowed us to induce Cre-mediated recombination for the purpose of tracing NSCs and their progeny at various time points. The pattern observed upon embryonic induction closely reflected the course of brain development. Tamoxifen induction at E13.5 labeled almost the entire cortex in the forebrain as well as the entire cerebellum including neurons and glia (). This coincides with the initiation of neural progenitor migration that contributes to different cortical layers in embryonic neural development (Sun et al., 2002). Induction at E17.5, when neurogenesis in the forebrain reaches completion, resulted in labeling of only the outer most layers of the cortex (), which stands in line with the inside-out pattern of cortex layer formation (Sun et al., 2002). Additionally, the thalamus and hindbrain were labeled at this time point. In the neonatal mouse brain, there is persistent mild but widespread lacZ activity, indicative of residual but rare progenitor cells throughout the parenchyma (). The most active neurogenic region at this time is the cerebellum (Herrup and Kuemerle, 1997), which showed intense lacZ staining following induction at E17.5 through P7 (). Mouse cerebellum development is considered to be complete by 3 weeks after birth, however our Nes73-CreERT2;Rosa26lacZ mice showed strong Cre activity in the anterior part of cerebellum when induced 4 and 8 weeks after birth (, and ; and see below). Nonetheless, in the anterior brain, by 4 weeks of age the SVZ and SGL are the most neurogenic regions as assayed by tamoxifen-induced Cre activity ().

Novel Cre activity. Nes73-CreERT2;Rosa26lacZ mice were treated with tamoxifen at 4 weeks of age and analyzed at 8 weeks (ac, eh, left and right panel of i). Abundant -Gal expression was detected in the anterior part of cerebellum ...

Adult NSCs modify their gene expression as they migrate and differentiate. In the SVZ, glial fibrillary acidic protein (GFAP) positive cells are considered to be stem cells (Doetsch et al., 1999). When differentiation starts and neuronal fate of the progenitor cells has been specified, cells begin to express doublecortin (DCX) and migrate into the OB through the RMS to finally become NeuN-positive mature neurons (Doetsch et al., 1999; Ming and Song, 2005). To determine the sites of primary Cre recombinase activity, we examined the SVZ of 4-week-old Nes73-CreERT2;Rosa26lacZ mice 48 h after a short pulse of tamoxifen, since both GFAP-positive neural stem cells and some transient amplifying progenitor cells express nestin. X-gal staining followed by immunohistochemistry (IHC) with GFAP or DCX antibody revealed that the majority of Cre activity resides in GFAP-positive SVZ cells close to the lateral ventricle, with only rare DCX-positive SVZ or RMS cells showing recombination (). This was further confirmed using an estrogen receptor antibody to show double labeling of Cre-ERT2-positive cells with the stem cell marker GFAP, and with S100, a marker of radial glia-derived ependymal cells (Supp. Info. Fig. 1) (Spassky et al., 2005). These studies indicate that the primary site of tamoxifen-activated Cre recombinase is the GFAP-positive, SVZ stem cell population.

Cre activity in adult NSC niches and migration targets. (a) Representative X-gal stained brain sections from mice 48 h after two tamoxifen administrations at P28 (12-h interval). X-gal signal was mainly restricted to SVZ (a1), with little or no signal ...

To measure the efficiency of tamoxifen-induced recombination in our Nes73-CreERT2 mice, we crossed them with the Rosa26YFP reporter line to generate Nes73-CreERT2;Rosa26YFP mice and then induced these mice with tamoxifen at 4 weeks of age. We then harvested brain sections from the induced mice at 6 weeks of age, and performed immunofluorescent double-labeling with GFP and Sox2 antibodies (Supp. Info. Fig. 2). The percentage of GFP/Sox2 double-positive cells divided by the number of Sox2 positive cells in the SVZ was used to determine recombination efficiency. This quantification analysis revealed that 75 4% of Sox2-positive cells in the SVZ have been targeted 2 weeks after a 5-day tamoxifen induction.

To further study the dynamics of stem/progenitor cell migration and differentiation, Nes73-CreERT2;Rosa26lacZ mice were induced at 4 weeks of age and examined by X-gal staining 2 or 4 weeks later ( and ). The dynamics of Cre-active cells in the hippocampus over time was not very dramatic (), however in the SVZ, an increase in the number of Cre active cells in an expanded ventricular area was evident 4 weeks after induction (). These results suggest a precursor-progeny relationship in which, after 2 weeks of induction, a significant number of new progenitor cells have been generated by stem cells and are beginning to disperse from the SVZ. Similarly, in the OB 2 weeks after induction, the X-gal positive cells were confined to a central cluster, whereas 4 weeks postinduction the cells were dispersed throughout the OB (). We interpret this result to indicate that at 2 weeks postinduction, cells are just arriving to the OB via the RMS and are confined to this central area, whereas at 4 weeks postinduction, these labeled cells have now dispersed throughout the OB. A similar, although more restricted, migration was also observed in hippocampus, where -Gal and NeuN double-positive neurons first appear close to the SGL 2 weeks after induction but by 4 weeks postinduction have migrated deeper into the granular layer ().

To explore the identity of the Cre-active cells, immunofluorescent double labeling was used to characterize Nes73-CreERT2;Rosa26lacZ mice 4 weeks after induction (). -Gal immunoreactivity was found in nestin and GFAP-positive neural stem/progenitor cells in the SVZ and SGL (). In the anterior part of the SVZ and SGL, DCX-positive neural progenitors also showed Cre activity (). In addition, a majority of the cells in the RMS express both -Gal and DCX (). Furthermore, NeuN-positive mature neurons that also retained -Gal immunoreactivity could be found in the HP and OB (). A small number of GFAP-positive astrocytes in the OB and the corpus callosum (CC) also expressed the reporter gene -Gal (), indicating the presence of Cre activity in multiple cell types in the NSC lineage. This result is consistent with recent quantitative lineage tracing studies (Lagace et al., 2007).

The significant amount of Cre activity induced in anterior cerebellum of adult mice was unexpected (). shows a representative eight-week-old brain from a mouse that was induced with tamoxifen at 4 weeks of age. The -Gal positive cells were mostly NeuN-positive inner granular layer (IGL) granule cells and Bergmann glia that extend long processes to the surface of the cerebellum (). Consistent with previous reports that Bergmann glia express NSC markers such as nestin and Sox2 (Mignone et al., 2004; Sottile et al., 2006), we found that Cre-active Bergmann glia also expressed the NSC marker nestin (). However, the Cre-ERT2 fusion transgene was also expressed in some Sox2-negative cells in the IGL (, middle panel), suggesting potential aberrant expression of the Nestin-CreERT2 transgene. Mild but reproducible tamoxifen-induced Cre activity was also observed in the piriform cortex (), which has also been reported to be a potential neurogenic region (Pekcec et al., 2006). We next assessed tamoxifen-induced Cre activity in other regions using whole mount X-gal staining, and found that the dorsal root ganglia (DRG) but not the spinal cord showed Cre activity (). Histologic examination revealed that less than half of the DRG neurons undergo Cre-mediated recombination (). In addition, Cre activity was detected in the optic nerve and trigeminal ganglia in mice induced at neonatal (, middle panel) or adult stages (, right panel). Collectively these data indicate that the nestin promoter/enhancer employed to generate this tamoxifen inducible transgene, exhibits remarkable fidelity to the endogenous neural expression with only a few potential sites of discrepancy.

Detailed analysis of traditional Nestin-Cre transgenic lines has revealed Cre activity outside the CNS, for example, in the kidney and in somite-derived tissues (Dubois et al., 2006). To determine whether Cre activity in the Nes73-CreERT2 mice was restricted to the nervous system, Nes73-CreERT2;Rosa26lacZ mice were induced for 5 days starting at P0 and analyzed at 8 weeks of age by whole-mount X-gal staining of internal organs including the heart, lung, liver, thymus, spleen, kidney, pancreas and stomach. With the exception of the esophagus, where neonatal but not adult exposure to tamoxifen induced Cre activity (, Supp. Info. Fig. 3) and stomach, where spontaneous lacZ activity is present in controls (, Supp. Info. Fig. 3) (Kwon et al., 2006), we found no evidence of obvious reporter expression in the absence or presence of tamoxifen (see ).

Cre activity is not observed in internal organs. Nes73-CreERT2;Rosa26lacZ mice were treated with vehicle (Veh) or tamoxifen (Tmx) at P0 for 5 days. Different organs were then dissected out at 8 weeks and subjected to whole mount X-gal staining. Endogenous ...

The rediscovery of neurogenesis in the adult brain has led to reawakened interest in the role of new neurons in the mature brain. The SVZ is a major site of neurogenesis for OB interneurons, although emerging evidence suggests additional roles. In the hippocampus, neurogenesis has been implicated in mood modulation and in learning and memory (Li et al., 2008; Lie et al., 2004; Zhao et al., 2008). On the dark side, stem/progenitor cells in the CNS have been implicated as the source of glioblastoma (Kwon et al., 2008; Sanai et al., 2005; Zhu et al., 2005). Specific ablation or activation of genes implicated in hippocampal function and in glioma can be achieved with our tamoxifen-inducible Cre transgene and we have developed successful models of both SVZ stem/progenitor cell-dependent induction of glioma and hippocampal stem/progenitor cell-dependent antidepressant insensitive mice using this tamoxifen-inducible Cre mouse line (Li et al., 2008; Llaguno et al., submitted).

Still, there is much to be learned about the precise role of neural stem cells in normal brain function and in associated pathologies. For example, in this report we describe novel sites of nestin-Cre recombinase activity. Whether this activity identifies previously undetected sites of neurogenesis or simply ectopic Cre expression remains to be rigorously determined. Of note, a second, independently derived transgenic line, Nes8-CreERT2, shows a similar pattern of inducible expression (data not shown) leading us to favor the conclusion that the expression outside the SVZ and SGZ is not due to position effects at the site of transgene insertion but rather is a reflection of the properties of the transgenic construct. Stem cells have been isolated from neonatal cerebellum and they are reported to be prominin/CD133-positive and Math1-negative (Klein et al., 2005; Lee et al., 2005). We observe Cre activity in the cerebellum from E17.5 through 8 weeks of age. Although diminishing over time, a clear gradient is observed that becomes progressively more anterior. The lacZ positive cells resulting from activation of the Rosa26 reporter possess the characteristic morphology of granule cells. In adult cerebellum, the Bergmann glia retain a morphology reminiscent of radial glia which can generate neurons and adult NSCs during brain development (Gotz and Barde, 2005; Merkle et al., 2004). In addition, Bergmann glia still express stem cell markers such as Sox2 and nestin (Mignone et al., 2004; Sottile et al., 2006). On the other hand, only rarely have cells with BrdU incorporation been observed in adult cerebellum, even after growth factor infusion (Grimaldi and Rossi, 2006). We also found that a number of cells in the anterior cerebellum targeted 2 days after acute tamoxifen administration were positive for NeuN but not GFAP or nestin (Supp. Info. Fig. 4), suggesting that the cre activity in the IGL was more likely due to promoter leakiness (Supp. Info. Fig. 4). Further study is needed to resolve this issue.

A series of similar inducible Nestin-Cre transgenes has recently been reported, although the extent of expression over time and expression outside the nervous system was not described (Supp. Info. Table 1) (Balordi and Fishell, 2007; Burns et al., 2007; Imayoshi et al., 2006; Kuo et al., 2006; Lagace et al., 2007). Eisch and co-workers recently described a tamoxifen-inducible Cre transgenic mouse line with no obvious Cre activity in the cerebellum upon tamoxifen induction (Lagace et al., 2007). The fact that our transgenic construct included only intron 2 of the nestin gene whereas their construct contained nestin exons 13 could account for this discrepancy (Zimmerman et al., 1994). It is possible that our more limited nestin construct might lack cerebellar-specific repressor sequences. Another potentially significant variation is the use of a Rosa26lacZ reporter line versus the Rosa26YFP reporter used by Lagace et al. (2007). Both the sensitivity of the reporter and perhaps the recombinogenic efficiency could in principle differ, leading to these discrepancies. We also observe Cre activity in the adult piriform cortex. This is in accordance with previous reports of BrdU incorporation in this region, leading to the suggestion of additional neurogenic niches (Pekcec et al., 2006).

We examined our mice for leakiness as well as for inducible transgene expression in the peripheral nervous system (PNS) and multiple organs. In contrast to many other Nestin reporter transgenic mice (Day et al., 2007; Dubois et al., 2006; Gleiberman et al., 2005; Li et al., 2003; Ueno et al., 2005), we found no evidence of obvious leakiness or of inducible transgene activation outside the CNS except in the PNS, where inducible expression was found both in the DRG and trigeminal ganglion, and in the esophagus. It is possible that our Nestin-CreERT2 transgene has a more restricted expression pattern or that the tamoxifen induction efficiency is lower in certain tissues. In addition, whole mount X-gal staining of the organs makes it difficult to capture rare Cre-positive cells if they do exist. DRG have been used to culture neurospheres (Li et al., 2007), and it will be of interest to determine whether our transgene is active in these progenitor cells, which would provide supportive evidence for the existence of additional neural stem/progenitor niches. Subsequent detailed lineage tracing of the Cre expressing cells will more clearly address this issue.

A 2.0 kb fragment of CreERT2 and SV40 polyA sequence of the pCre-ERT2 vector (Feil et al., 1997) were amplified using a PCR technique that also generated 5 Not1 and 3 Spe1 sites. After enzymatic digestion, purified fragment was ligated to an 8.9 kb fragment from pNerv (Panchision et al., 2001; Yu et al., 2005) digested with Not1 and Xba1. The resulting pNes-CreERT2 construct contains a 5.6 kb rat nestin 5 genetic element from pNerv, a 2.0 kb CreERT2 and SV40 polyA sequence from pCre-ERT2 and a 668 bp of reversed second intron of rat nestin from pNerv (). After Sal1 digestion, an 8.3 kb band was purified and microinjected into the pronuclei of fertilized eggs from B6D2F1 mice. Among 28 pups born after two rounds of transgenic injection, six contained the transgene, and four of them transmitted to germline. Rosa26lacZ mice were obtained from Jackson Laboratories (Bar Harbor, ME), Rosa26YFP mice were kindly provided by Dr. Jane Johnson. All the mice were maintained in a mixed genetic background of C57BL/6, SV129 and B6/CBA. Nestin73-CreERT2; Rosa26lacZ mice were generated by crossing male Nestin-CreERT2 mice with female Rosa26lacZ mice. Genotyping of the mice was performed as described previously (Kwon et al., 2006). All mouse protocols were approved by the Institutional Animal Care and Research Advisory Committee at the University of Texas Southwestern Medical Center.

Tamoxifen (Sigma-Aldrich, St. Louis, MO) was dissolved in a sunflower oil (Sigma-Aldrich, St. Louis, MO)/ethanol mixture (9:1) at 6.7 mg/ml. For initial screening of the embryonic induction of the transgenic lines, 150-l tamoxifen (1 mg) or vehicle (sunflower oil/ethanol mixture only) was injected intraperitoneally into pregnant mice at embryonic day E12.5 (E12.5 hereafter). Embryos were dissected out 2 days later and subjected to X-gal staining. For in utero induction, 150-l tamoxifen (1 mg) or vehicle was injected intraperitoneally into pregnant mothers at E13.5 or E17.5, and pups were analyzed 1 month after birth. For neonatal induction, 12.5-l tamoxifen (83.5 mg/kg body weight) or vehicle per gram of mouse body weight was injected into lactating mothers (tamoxifen can be delivered to pups through the mothers milk) at P0 or P7, once a day for 5 days and the pups were analyzed 4 weeks after the first induction. For induction in adult mice, 12.5-l tamoxifen (83.5 mg/kg) or vehicle per gram of body weight was injected intraperitoneally into 4- or 8-week-old mice twice a day for five consecutive days and then analyzed 2 or 4 weeks after the first induction.

Mice were dissected and perfused as previously described (Kwon et al., 2006). For whole mount X-gal staining, the embryos or organs were carefully dissected out, washed with phosphate-buffered saline (PBS), and then fixed in 2% (w/v) paraformaldehyde (PFA; in PBS) for 1 h at 4C. Postnatal brains were postfixed in 2% PFA overnight (O/N) at 4C, embedded in 2.5% chicken albumin sagittally or coronally, and then cut into 50-m thick sections by vibratome (Leica, Nussloch, Germany). Every fifth sagittal section or 12th coronal section was chosen to perform X-gal staining and comparable sections were selected for further immunostaining according to the X-gal staining result. X-gal staining of organs and sections was performed as described (Kwon et al., 2006).

Four Nestin73-CreERT2;Rosa26YFP mice were induced at 4 weeks of age as described above and perfused with 2% PFA at 6 weeks of age. The brains were dissected out, postfixed in 4% PFA O/N at 4C, processed and embedded in paraffin blocks. Five-m thick sagittal sections were cut until the lateral ventricle was gone. H&E staining was performed on every fifth slide to determine comparable sections. Every 10th of comparable sections was subjected to GFP (Aves Labs, Tigard, OR) and Sox2 (Chemicon, Temecula, CA) immunofluorescence staining, and three random regions of the frontal SVZ of each section were selected for counting. The efficiency was determined by the percentage of GFP (mean 203)/Sox2 (mean 270) double-positive cells out of the total Sox2-positive cells in SVZ.

Free-floating immunofluorescence staining was performed on 50-m thick sections. Antibodies used for the staining were against -galactosidase (ICN, Aurora, OH), GFAP, nestin (BD Biosciences, Bedford, MA), doublecortin (Santa Cruz Biotechnology, Santa Cruz, CA), NeuN (Chemicon, Temecula, CA), Mash1 (BD Biosciences, Bedford, MA), S100 (Sigma-Aldrich, St. Louis, MO). Alexar-488 or Alexar-555 conjugated goat anti-mouse or anti-rabbit (Molecular Probes, Eugene, OR) and Cy2 or Cy3 donkey anti-goat, anti-rabbit antibodies (Jackson Immunoresearch, West Grove, PA) were used to visualize primary antibody staining. Images were taken on a Zeiss LSM 510 confocal microscope (Carl Zeiss, Jena, Germany). For ER and Sox2 staining, 5-m thick paraffin sections were first stained with estrogen receptor antibody (Lab Vision, Fremont, CA) and visualized by DAB substrate with nickel solution (Vector Laboratories, Burlingame, CA). The slides were then washed with PBS three times, stained with Sox2 antibody (Chemicon, Temecula, CA), and visualized by Vector NovaRED (Vector Laboratories, Burlingame, CA). Images were taken with a Nikon 2000 CCD camera (Nikon, Japan). All images were assembled using Adobe Photoshop CS and Illustrator CS (Adobe Systems Incorporated, San Jose, CA).

We thank Steven Kernie for providing pNerv plasmid, Jane Johnson and Frank Costantini for providing Rosa26YFP mice, Steven McKinnon, Shirley Hall, and Linda McClellan for technical assistance, Renee McKay for reading the manuscript, and Jane Johnson, James Battiste, Jing Zhou, and Yun Li for discussion and suggestions.

Additional Supporting Information may be found in the online version of this article.

Read the original here:
Inducible Site-Specific Recombination in Neural Stem ...

How are Adult Stem Cells Turned into Treatments? | Boston …

Currently, blood stem cells are the only type of adult stem cell used regularly for treatment; they have been used since the late 1960s in the procedure now commonly known as bone marrow transplant. Transplants of neural stem cells have been tried in small numbers of patients with brain disorders such as Parkinson disease, and the FDA recently approved a clinical trial of neural stem cells for spinal cord injury.

Preliminary research in animals has found that bone marrow stromal cells, injected into a damaged heart, can have beneficial effects. And researchers at Childrens Hospital Boston have shown in a mouse model that the same cells, injected into the blood, help protect against chronic lung disease in premature newborns.

In some cases, it may be possible to infuse the stem cells into the blood, as in a bone marrow transplant. The cells find their own way to the proper location and begin forming the cells and tissues needed. In other cases, the cells may need to be injected directly into the organ or tissue that needs them.

The ultimate goal is for the cells to take up residence in their proper places in the body, divide repeatedly and form functioning tissuesor repair diseased tissue. Its not always clear how this happens. In some cases, the transplanted cells may become part of the tissue or organ; in others, they may secrete growth factors that stimulate cells already residing there.

For adult stem cells to be successful treatments, they must:

1) Reproduce in large enough quantities to provide the amounts needed for treatment. Some adult stem cells have a very limited ability to divide, making it difficult to multiply them in large numbers. Scientists around the world are trying to find ways of encouraging them to multiply. The Stem Cell Program at Boston Childrens Hospital, for example, recently discovered that a drug called PGE2 can multiply numbers of blood stem cells. PGE2 is now being tested in patients with leukemia and lymphoma to see if it will help them rebuild their blood systems.

2) Create the needed cell types, either in the laboratory or after theyve been transplanted into the body.

3) Be safe. A host of clinics around the world offer supposed stem-cell therapies with claims of complete success, but these treatments must still be considered experimental and potentially risky until much more work is done to ensure their safety. For example, when adult stem cells are provided from a donor, precautions must be taken to avoid rejection by the patients immune system. Unless the patient is his or her own donor, or unless a donor is found with an identical tissue type, the patient will need to take powerful drugs to suppress the immune system so the transplanted cells or tissues wont be rejected. In addition, if adult stem cells are manipulated incorrectly, there is a risk of cancer.

4) Stay alive and remain functional for the rest of the patients life, continuing to maintain a healthy tissue or organ.

The rest is here:
How are Adult Stem Cells Turned into Treatments? | Boston ...

Adult vs. Embryonic Stem Cells – Brown University

Advantages of Adult Stem Cells

Both lines of stem cells have an enormous therapeutic potential. While embryonic stem cells offer the potential for wider therapeutic applications, adult stem cells avoid the ethical issues roused by embryonic stem cell research. Therefore, many stem cell therapies are currently being tested using adult stem cells. Additionally, adult stem cells offer the potential for autologous stem cell donation, which may help to avoid issues of immune rejection in certain situations.

It is also known that upon injection into mice with compromised immune systems, undifferentiated embryonic stem cells elicit the formation of a benign tumor called a teratoma. This tumor formation causes scientists to doubt the therapeutic applicability of embryonic stem cells. It is not yet known whether similar results are observed with adult stem cells [17].

Advantages of Embryonic Stem Cells

The advantages of embryonic stem cells is that they offer one cell source for multiple indications. They provide the potential for a wider variety of applications than do adult stem cells. Additionally, they theoretically have the possibility of being immuno-privileged, due to their highly undifferentiated state. A privileged immune status would remove one of the main barriers of stem cell therapies, as self rejection is one stem cell therapys main complications [17]. The idea that embryonic stem cells can be immune privilaged, must be viewed skeptically, however, as this theory has not yet been proven.

Another advantage of embryonic stem cells, is that they appear to be immortal in vitro, while adult and differentiated stem cells cannot be cultured indefinitely in the lab. Once differentiated, these stem cells seem to die off like typical tissue cells.

Click Here to go Back to: Stem Cell Types

Click Here to go to: Stem Cell Classification

Click Here to go to: Clinical Therapies

Click Here to go to: Stem Cells and Research

Click Here to go to: History of Stem Cells

Click Here to go to: Stem Cell Funding

Click Here to go to: Challenges

Read more:
Adult vs. Embryonic Stem Cells - Brown University